BRAF and melanoma: Finally, clinical results from ongoing combination treatment assays of different ICIs combinations will give new hope to patients who are unresponsive to current therapies, like those observed with a combination of a MEK inhibitor and a BRAF inhibitor, to overcome resistance of melanoma to targeted therapy.